Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

被引：1
|
作者：
Inyang, Eno [1 ]
Aktas-Samur, Anil [2 ]
Munshi, Nikhil C. [3 ]
Leblebjian, Hour [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
666
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib,epirubicin and dexamethasone in patients with multiple myeloma
    郝倩云
    China Medical Abstracts(Internal Medicine), 2016, 33 (04) : 230 - 230
  • [42] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
    Nooka, Ajay
    Kaufman, Jonathan
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah
    Anderson, Larry
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas
    Usmani, Saad
    Richardson, Paul
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
  • [43] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
    Anderson, Larry D., Jr.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Voorhees, Peter M.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [44] Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Gleason, Charise
    Boise, Lawrence
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina D.
    Efebera, Yvonne A.
    Costello, Caitlin L.
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [46] Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
    Hansen, Doris K.
    Gautam, Santosh
    Lafeuille, Marie-Helene
    Rossi, Carmine
    Moore, Bronwyn
    Tardif-Samson, Anabelle
    Thompson-Leduc, Philippe
    Fu, Alex Z.
    Cortoos, Annelore
    Kaila, Shuchita
    Fonseca, Rafael
    BLOOD, 2023, 142
  • [47] MATHEMATICAL MODELS FOR EARLY DETECTION OF RELAPSE IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE.
    Otani, Y.
    Bottino, D.
    Gupta, N.
    Vakilynejad, M.
    Tanigawara, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S39 - S39
  • [48] Outcomes and Clinical Features of Patients with 1q+Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone
    Schmidt, Timothy M.
    Joseph, Nisha
    Odikadze, Levani
    Heffner, Leonard
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Gupta, Vikas A.
    Boise, Lawrence H.
    Jaye, David L.
    Lonial, Sagar
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    BLOOD, 2018, 132
  • [49] Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients
    Buda, Gabriele
    Orciuolo, Enrico
    Galimberti, Sara
    Pelosini, Matteo
    Petrini, Mario
    ANNALS OF HEMATOLOGY, 2011, 90 (09) : 1115 - 1116
  • [50] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Gleason, Charise
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Steuer, Conor E.
    Kumar, Mukesh
    Casbourne, Daniela
    Langston, Amelia A.
    Watson, Melanie
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345